Keystone Heart is focused on protecting the brain from emboli to reduce the risk of brain infarcts during TAVR, atrial fibrillation ablation and other structural heart procedures.

Latest News

Share this
News

Join Keystone Heart at TCT2018

We invite you to explore and discuss with world-renown physicians the importance of complete cerebral embolic protection with TAVR. Please join us for the Keystone Heart Lunch Symposium during TCT 2018where we will share current research on cerebral embolic debris during TAVR, progress of the US REFLECT trial using TriGUARD 3™, early US experience and commentary with TriGUARD 3™.

The Case for Complete Cerebral Embolic Protection-REFLECT
Saturday, September 22, 2018| Program: 1:00 pm-2:00 pm
Presentation Theater 4 (Exhibit Hall)| San Diego Convention Center

REGISTER HERE

Agenda:

1:00 pm |  Current Cerebral Embolic Protection Landscape – Keystone Heart TriGUARD Data Review
Jeffrey Moses

1:10 pm  |  REFLECT Clinical Trial Update with TriGUARD 3
Tamim Nazif

1:20 pm  |  TriGUARD 3 Case Presentation- Early US Experience
Michael Mack

1:28 pm  |  TriGUARD 3 Post-Market EU Registry Plan
Darius Dudek

1:35 pm  |  The Importance of DW-MRI and Longitudinal Impact of Cerebral Ischemic Lesions
John Forrest

1:45 pm  |  Cerebral Embolic Protection Panel Discussion
Alexandra Lansky

2:00 pm  |  Adjourn

 

TriGUARD 3™ is an investigational device and not commercially available in the United States.

Share

No Comments

Leave a reply